THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Shanghai HeartCare Medical Technology Corporation Limited**, you should at once hand this circular with the enclosed form of proxy to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

This circular appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

Shanghai HeartCare Medical Technology Corporation Limited

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING

Capitalized terms used in this cover page shall have the same meanings as defined in this circular.

A letter from the Board is set out on pages 4 to 19 of this circular. Notice convening the EGM to be held at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC at 10:00 a.m. on Friday, November 13, 2026 is set out on pages 20 to 22 of this circular. A form of proxy for use at the EGM is enclosed and is also published on the websites of the Hong Kong Stock Exchange (www.hkexnews.hk) and the Company (www.heartcare.com.cn).

Shareholders who intend to appoint a proxy to attend the EGM shall complete and return the form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time appointed for the EGM (i.e. no later than 10:00 a.m. on Thursday, November 12, 2026) or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not prevent you from attending and voting in person at the EGM or any adjournment thereof should you so wish.

For the avoidance of doubt and for the purpose of the Hong Kong Stock Exchange, holders of treasury Shares, if any, shall abstain from voting at the EGM.

Reference to times and dates in this circular are to Hong Kong local time and dates.

October 29, 2026

CONTENTS

Page

DEFINITIONS 1

LETTER FROM THE BOARD 4

NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING 20

In this circular, the following expressions shall have the meanings set out below unless the context requires otherwise:

"Articles of Association" or "Articles"	the articles of association of the Company, as amended from time to time
"Board of Directors" or "Board"	the board of directors of the Company
"China" or "PRC"	the People's Republic of China, for the purpose of this circular, excluding the regions of Hong Kong, Macao Special Administrative Region of the People's Republic of China and Taiwan
"Company"	Shanghai HeartCare Medical Technology Corporation Limited (上海心瑋醫療科技股份有限公司), a joint stock limited liability company incorporated in the PRC, whose H Shares are listed on the Hong Kong Stock Exchange (Stock Code: 6609)
"Director(s)"	the director(s) of the Company
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in Renminbi by domestic investors and are not listed on any stock exchange
"EGM"	the 2026 third extraordinary general meeting of the Company to be held, the notice of which is set out in pages 20 to 22 of this circular
"Group"	the Company and its subsidiaries, or any one of them as the context may require
"H Share(s)"	overseas listed foreign share(s) in the ordinary share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong Dollars and listed on the Hong Kong Stock Exchange
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC

"Hong Kong Listing Rules" or "Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
"Hong Kong Stock Exchange" or "Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Latest Practicable Date"	October 26, 2026, being the latest practicable date for the purpose of ascertaining certain information contained in this circular prior to its publication
"Main Board"	the stock market (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"Nomination Committee"	the nomination committee of the Board
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended from time to time
"Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, comprising Domestic Share(s), Unlisted Foreign Share(s) and H Share(s)
"Shareholder(s)"	holder(s) of the Shares
"Shanghai Stock Exchange"	the Shanghai Stock Exchange (上海證券交易所)
"Shenzhen Stock Exchange"	the Shenzhen Stock Exchange (深圳證券交易所)
"Third Session of the Board"	the third session of the Board, to be elected at the EGM
"Treasury share(s)"	has the meaning ascribed to it under the Hong Kong Listing Rules
"Unlisted Foreign Share(s)"	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and paid for in currency other than RMB by foreign investors and are not listed on any stock exchange

"Unlisted Share(s)"	Domestic Shares and Unlisted Foreign Shares
"%"	per cent

Shanghai HeartCare Medical Technology Corporation Limited
上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

Executive Directors:
Mr. WANG Guohui *(Chairman)*
Ms. ZHANG Kun
Mr. WEI Jiawei

Non-executive Directors:
Mr. CHEN Shaoxiong
Mr. CHEN Gang

Independent Non-executive Directors:
Mr. GUO Shaomu
Mr. FENG Xiangqian
Mr. GONG Ping

Registered office and headquarters in the PRC:
Building 38
No. 356, Zhengbo Road
Lingang New District
Pilot Free Trade Zone
Shanghai, PRC

Principal place of business in Hong Kong:
Room 1901, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

October 29, 2026

To the Shareholders

Dear Sir/Madam,

PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING

I. PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS

Reference is made to the announcement of the Company dated October 26, 2026. The term of office of the second session of the Board will expire in November 2026. Pursuant to the Articles of Association, the Directors are elected and appointed by the Shareholders at a Shareholders' meeting for a term of three years, which is renewable upon re-election and re-appointment. Accordingly, all the existing Directors and the proposed new Director shall be elected to the Third Session of the Board upon the expiry of the term of the second session of the Board.

In accordance with the provisions of the Articles of Association, the Third Session of the Board shall comprise nine (9) Directors, of which not less than one-third shall be independent non-executive Directors. The term of office of the Directors of the Third Session of the Board shall be three (3) years with effect from the date of approval at the EGM. The Company will enter into a service contract with each of the re-elected and newly appointed Directors.

The proposed Directors of the Third Session of the Board are as follows:

Executive Directors

(1) Mr. WANG Guohui

(2) Ms. ZHANG Kun

(3) Mr. WEI Jiawei

Non-executive Directors

(4) Mr. CHEN Gang

(5) Mr. CHEN Shaoxiong

(6) Mr. LU Xubo

Independent Non-executive Directors

(7) Mr. GUO Shaomu

(8) Mr. FENG Xiangqian

(9) Mr. GONG Ping

All proposed Directors have respectively confirmed that they have no disagreement in respect of the nomination.

II. BIOGRAPHICAL DETAILS OF THE PROPOSED DIRECTORS

Biographical details of the proposed Directors of the Board in the third session are set out as follows:

EXECUTIVE DIRECTORS

Mr. WANG Guohui (王國輝), aged 49, is one of our single largest Shareholders and founders. As our director and chief executive officer since the establishment of our Company in June 2016, he was redesignated as our executive Director and appointed as our chairman of the Board on November 23, 2020. He is primarily responsible for the overall management of our Company.

Mr. Wang has over 21 years' experience in the fields of R&D and commercialization of medical devices. Prior to the founding of our Company, he worked at Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械(集團)有限公司, the "**MicroPort**"), a company primarily engaged in the R&D, manufacturing and marketing of medical devices and a subsidiary of MicroPort Scientific Corporation (微創醫療科學有限公司, the "**MicroPort Scientific**"), whose shares are listed on the Main Board of the Stock Exchange (stock code: 00853.HK), from August 2004 to February 2012. MicroPort Scientific was then a leading medical technology company that was developing, manufacturing and selling high-end medical devices in the PRC whose products included those used for vascular diseases and disorders, such as cardiovascular, neurovascular, aortic and peripheral vascular, as well as devices for cardiology, electrophysiology, orthopedics and diabetes. Mr. Wang was primarily responsible for the management of qualify system and registration regulations at MicroPort. From March 2012 to November 2014, he was the senior director of quality regulations at Angiocare Medical Technology Corporation Limited (上海安通醫療科技有限公司, the "**Angiocare**"), a company primarily engaged in the development, production and sale of medical devices for renal denervation, where he was primarily responsible for quality control and products registration. From December 2014 to November 2015, Mr. Wang served as the deputy general manager of Essen Technology (Beijing) Corporation Limited (易生科技(北京)有限公司, the "**Essen Technology**"), a company primarily engaged in interventional cardiovascular devices in China with a current focus on the R&D and commercialization of DES products, where he was primarily responsible for the overall management of the company. From December 2015 to May 2016, he was the deputy general manager of Shanghai Bio-heart Biological Technology Co., Ltd. (上海百心安生物技術股份有限公司), which is a leading interventional cardiovascular device company in China with current focus on bioresorbable scaffolds and renal denervation, where he was primarily responsible for quality control and products registration.

In November 2007, Mr. Wang was certified as a standardization engineer by Shanghai Municipal Human Resources Bureau (上海市人事局), currently known as Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局). In November 2019, he was appointed as a committee member by the Youth Committee of Shanghai Stroke Association (上海卒中學會青年理事會). In September 2020, Mr. Wang was appointed as a professional consultant to the Life Science Blue Bay of Lin-gang Special Area (臨港新片區生命藍

灣) by China (Shanghai) Pilot Free Trade Zone Lin-gang Special Area Administration (中國(上海)自由貿易試驗區臨港新片區管理委員會) and Shanghai Lin-gang Economic Development (Group) Corporation Limited (上海臨港經濟發展(集團)有限公司). Mr. Wang was also appointed as a committee member of the Cardiovascular Implant Sub-Technical Committee of the National Standardization Technical Committee for Surgical Implants and Orthopedic Devices (全國外科植入物和矯形器械標準化技術委員會心血管植入物分技術委員會) by the Standardization Administration of the PRC (國家標準化管理委員會), a vice managing committee member of the Intervention Medical Engineering Committee of the Shanghai Biomedical Engineering Society (上海市生物醫學工程學會介入醫學工程專會副主任委員), and was named as a "Shanghai Industry Elite" (上海產業菁英). In December 2022, he was certified as a senior engineer by Shanghai Municipal Human Resources and Social Security Bureau.

Mr. Wang obtained his bachelor's degree in marine engineering management from Dalian Maritime University (大連海事大學) in the PRC in July 2000. He received his master's degree in applied chemistry from Shanghai University (上海大學) in the PRC in March 2005, and a degree of executive master of business administration from Tsinghua University (清華大學) in the PRC in January 2016.

Ms. ZHANG Kun (張坤), aged 49 and formerly named Zhang Ye (張葉), was redesignated as our executive director on November 23, 2020. She joined our Company as a supervisor in April 2018 and has served as a Director of our Company since September 2019. Ms. Zhang was the deputy general manager of our Company from November 23, 2020 to March 27, 2025. She is currently the legal representative of the Company's subsidiary, Shanghai Weiqi Medical Device Co., Ltd and is primarily responsible for its operations.

Ms. Zhang has over 25 years' experience in the fields of the R&D and commercialization of medical devices. Prior to the founding of our Company, she was the sales representative of Shanghai Zhenwei Science and Trade Corporation Limited (上海真維科貿有限公司), a company mainly engaged in the distribution of medical devices, from August 2000 to May 2002, where she was primarily responsible for the development, sale and marketing of the interventional products in Shanghai area. From May 2002 to March 2004, she was the regional sales manager in charge of Shanghai area at MicroPort and was then promoted to the head of marketing department and medical affairs department during the period from March 2005 to May 2009. From May 2009 to January 2011, she served as the national marketing director of Shanghai MicroPort EP MedTech Corporation Limited (上海微創電生理醫療科技股份有限公司), a company primarily engaged in the R&D, manufacturing and marketing of medical devices and equipment and a subsidiary of MicroPort Scientific where she was primarily responsible for the marketing of the company. From December 2012 to November 2014, Ms. Zhang was the director of clinical experiment department at Angiocare, where she was primarily responsible for the management of clinical experiments and the marketing of products. From November 2014 to October 2020, she was the deputy general manager at Essen Technology, where she was primarily responsible for the overall management of the company. Ms. Zhang has served as the director of the Hong Kong United Future Foundation (香港共融未來基金會) since October 2023; she also became a member of the Beijing Women's Association for Hong Kong, Macau, Taiwan and Overseas (北京港澳台僑婦女聯誼會) in 2024.

Ms. Zhang obtained her bachelor's degree in mechanical and electrical engineering from Beijing Academy of Armored Forces Engineering (北京裝甲兵工程學院) in the PRC in July 2000. She received her master's degree in business administration from the City University of Hong Kong in February 2017. Since 2017, Ms. Zhang has held various positions at the City University of Hong Kong Executive Master of Business Administration (Chinese) Alumni Association (香港城市大學EMBA(中文)校友會, the "**EMBA (Chinese) Alumni Association of CityU**"). In September 2018, she was appointed as the deputy secretary-general for a term of two years from 2017 to 2019 by EMBA (Chinese) Alumni Association of CityU Limited (香港城市大學行政人員工商管理碩士(中文)校友會有限公司). Subsequently since December 2019, Ms. Zhang has been serving as a council member of EMBA (Chinese) Alumni Association of CityU for consecutive terms from 2019 to 2021, and 2021 to 2024. In December 2019, she was also appointed as a full-time deputy vice-president (devices) of the Biomedicine Professional Committee (生物醫藥專業委員會) of EMBA (Chinese) Alumni Association of CityU, certified as the founding member and appointed as the consultant to the presidential council of the EMBA (Chinese) Alumni Association of CityU.

Mr. WEI Jiawei (韋家威), aged 49, joined our Company in September 2020 and was appointed as the deputy general manager in November 2020. He was redesignated as our executive director on June 10, 2022. He was appointed as the senior vice president and chief marketing officer of our Company in March 2025, primarily responsible for sales and marketing management of our Company.

Mr. Wei has extensive experience in the field of marketing and sale of medical devices. Between September 2005 to December 2008, he worked in the BSC International Medical Trading (Shanghai) Corporation Limited (波科國際醫療貿易(上海)有限公司). From July 2008 to July 2018, Mr. Wei was first a regional sales manager in Ev3 Medical Devices (Beijing) Corporation Limited (醫偉司安醫療器材(北京)有限公司) and then promoted to the manager of its national new business development department of Covidien Healthcare International Trading (Shanghai) Corporation Limited (柯惠醫療器材國際貿易(上海)有限公司), both companies being the subsidiaries of Medtronic plc. He was a deputy general manager of sales of Jiangsu Nico Medical Technology Corporation Limited (江蘇尼科醫療器械有限公司) from August 2018 to August 2020.

Mr. Wei obtained his bachelor's degree in chemical pharmaceutical technology from East China University of Science and Technology (華東理工大學) in the PRC in July 1999.

NON-EXECUTIVE DIRECTORS

Mr. CHEN Gang (陳剛), aged 43, joined our Company in June 2020 as a Director and was redesignated and served as our non-executive director from November 2020 to August 2022. He was then appointed as our non-executive director on November 8, 2023. He is primarily responsible for providing strategic advice and recommendations on the operations and management of our Company.

Mr. Chen has over 18 years' experience in financial industry. From 2007 to 2011, Mr. Chen served as a project leader at L.E.K. Consulting (Shanghai) Co., Ltd. (艾意凱諮詢(上海)有限公司). Where he was primarily responsible for business strategy, merger and acquisition advisories for healthcare and life sciences clients. From 2013 to 2015, Mr. Chen worked at Vivo Capital Equity Investment Management (Shanghai) Co., Ltd. (維梧股權投資管理(上海)有限公司), where he was primarily responsible for investment due diligence, deal executions and portfolio management. From 2015 to 2017, Mr. Chen worked at Shanghai Aland Investment Holdings Co., Ltd. (上海艾蘭得投資控股有限公司). From 2017 to 2019, Mr. Chen worked at Jiaxing Jifeng Equity Investment Management Co., Ltd. (嘉興濟峰股權投資管理有限公司). Mr. Chen joined LYFE Capital Equity Investment Management (Shanghai) Co., Ltd. (洲嶺私募基金管理(上海)有限公司) as its partner from March 2019 to July 2022.

In his capacity as an investor, Mr. Chen served at various capacity for the following companies:

- From June 2018 to August 2020, as a director in Hangzhou Kangji Medical Instrument Co., Ltd. (杭州康基醫療器械有限公司) and from March 2020 to April 2022, Mr. Chen served as a non-executive director of Kangji Medical Holdings (康基醫療控股有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 9997).

- From October 2017 to November 2019, as a non-executive director at Cardiolink Science (Shenzhen) Medical Technology Development Co., Ltd. (科睿馳(深圳)醫療科技發展有限公司).

- From October 2020 to September 2021, as a non-executive director of Hangzhou Sciwind Biotech Co., Ltd. (杭州先為達生物科技有限公司).

- From November 2020 to June 2021, as a non-executive director at BirdoTech (Shanghai) Medical Technology Corporation Limited (都創(上海)醫藥科技股份有限公司).

- From December 2020 to April 2022, as a non-executive director of Nanjing Yoko Pharma Biotechnology Medicine Corporation Limited (南京優科生物醫藥股份有限公司).

- From April 2021 to August 2022, as a non-executive director of Hangzhou Jianjia Robot Co., Ltd (杭州鍵嘉機器人有限公司).

- From June 2018 to December 2020, as a supervisor at Sino Medical Sciences Technology Inc. (賽諾醫療科學技術股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688108).

- From November 2020 to September 2022, as a supervisor of Jiangsu Recbio Technology Co., Ltd. (江蘇瑞科生物技術股份有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 2179).

- From January 2018 to February 2023, as a non-executive director of Baicare Biotechnology Co., Ltd (北京百康芯生物科技有限公司).

- From July 2018 to September 2024, as a non-executive director of Beijing Anngeen Biotechnology Co., Ltd. (北京安智因生物技術有限公司).

Mr. Chen is currently serving the following positions outside our Group:

- Since May 2020, as a non-executive director of Shanghai Zhenge Biotech Co., Ltd. (上海臻格生物技術有限公司), a company primarily engaged in biologics CDMO service for biopharma and biotech companies.

- Since September 2020, as a non-executive director of Shenzhen ReeToo Biotech Co., Ltd. (深圳市瑞圖生物技術有限公司), a company primarily engaged in innovative AI-enhanced IVD products.

- Since January 2021, as a non-executive director of Shenzhen Edge Medical Robotics Co. Ltd. (深圳市精鋒醫療科技有限公司), a company primarily engaged in surgical treatments robotics.

- Since January 2021, as a supervisor of LYFE Capital Equity Investment Management (Shanghai) Co., Ltd. (洲嶺私募基金管理(上海)有限公司).

- Since February 2021, as a non-executive director of Shanghai ShenQi Medical Technology Co. Ltd. (上海申淇醫療科技有限公司), a company primarily engaged in interventional medical devices.

- Since September 2021, as a supervisor of Jixin (Shanghai) Enterprise Management Consulting Co., Ltd. (濟鑫(上海)企業管理諮詢有限公司).

- Since September 2021, as a supervisor of Jizhen (Shanghai) Enterprise Management Consulting Co., Ltd. (濟振(上海)企業管理諮詢有限公司).

- Since February 2022, as a non-executive director of MediLink Therapeutics (Suzhou) Co., Ltd. (蘇州宜聯生物醫藥有限公司).

- Since July 2022, as a director of LYFE Global Connection Private Limited.

- Since July 2023, as a board director of Fong's Engineering & Manufacturing Pte Ltd, a company based in Singapore engaged in medical device CDMO manufacturing.

- Since November 2025, as a director of Jiangsu Yaolingke Medical Technology Co., Ltd. (江蘇耀嶺科醫療科技有限公司).

- Since March 2026, as a director of Jiangsu Kesen Medical Devices Co., Ltd. (江蘇科森醫療器械有限公司).

Mr. Chen received his bachelor's degree in clinical medicine from Shanghai Medical School of Fudan University (復旦大學上海醫學院) in the PRC in July 2007 and master's degree in business administration from Northwestern University Kellogg School of Management in the U.S. in June 2013.

Mr. CHEN Shaoxiong (陳少雄), aged 64, was appointed as our non-executive director on November 9, 2022. He has worked at the Shanghai Biopharmaceutics Industry Association ("**SBIA**") since May 2003 and is currently serving as the secretary general and executive president of SBIA. Mr. Chen was also appointed as the chairman of Shanghai Shenjiang Medical Science and Technology Development Foundation (上海申江醫學科技發展基金會) in May 2023 and began serving as an independent director of Shanghai Tellegen Life Technology Co., Ltd. (上海透景生命科技股份有限公司), a company listed on the Shenzhen Stock Exchange (300642.SZ) in December 2023. Mr. Chen was also appointed as the independent non-executive director of Both Engineering Technology Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 601133.SH) with effect from March 14, 2024. He was also appointed as the independent non-executive director of Shanghai No.1 Pharmacy Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 600833.SH) with effect from June 21, 2024. Prior to joining SBIA, Mr. Chen Shaoxiong worked at Shanghai No.1 Biochemical and Pharmaceutical Co., Ltd. and its predecessor, Shanghai Biochemical Pharmaceutical Factory, between July 1984 and April 2003. Mr. Chen Shaoxiong has also served as the secretary general of the award committee of the C.C. Tan Life Science Award since May 2008 and the vice president of the Shanghai Federation of Industrial Economics: Shanghai Federation of Economic Organization since January 2010.

Mr. Chen Shaoxiong obtained his bachelor's degree in agriculture from the School of Agriculture and Biology of Shanghai Jiao Tong University (formerly known as Shanghai School of Agriculture) in July 1984, and he further obtained his executive master's degree in business administration from Antai College of Economics and Management at Shanghai Jiao Tong University in June 2010, and his doctorate of business administration from the Grenoble Ecole De Management in France in February 2018. Mr. Chen Shaoxiong has also been a qualified principal senior engineer since December 2018.

Mr. LU Xubo (魯旭波), aged 46, has served as a founding partner and the head of risk and compliance of FV Asset Management Hangzhou Co., Ltd. (杭州安益資產管理有限公司) since July 2016.

Mr. Lu has served as a director of Zhejiang Xiangyin Technology Co., Ltd. (浙江祥音科技有限公司) since April 2017, and as the secretary-general (秘書長) of Zhejiang Comfort Think Tank Education Foundation (浙江安逸智庫教育基金會) since January 2018. He has served as an independent non-executive director of Shanghai Bio-heart Biological Technology Co., Ltd. (上海百心安生物技術股份有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 2185.HK), since November 2020.

From October 2004 to October 2005, Mr. Lu was responsible for legal supervision at Fuyang Fuchun Shanju Leisure Business Co., Ltd. (富陽富春山居休閒事業有限公司). From December 2005 to June 2016, Mr. Lu served as assistant to the board secretary, securities affairs representative, investment department manager, supervisor, director and board secretary at Zhejiang Kangsheng Co., Ltd. (浙江康盛股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002418.SZ). From June 2020 to September 2020, Mr. Lu served as an executive director and the general manager of Hangzhou Zhidian Network Technology Co., Ltd. (杭州質點網絡科技有限公司). From August 2014 to August 2020 and from June 2022 to March 2025, Mr. Lu served as an independent director of Shanghai Kinetic Medical Co., Ltd. (上海凱利泰醫療科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300326.SZ).

Mr. Lu obtained his bachelor's degree in law from Zhejiang University of Finance and Economics (浙江財經大學) in the PRC in June 2003. He obtained the Legal Professional Qualification of the PRC (中華人民共和國法律職業資格) , issued by the Ministry of Justice of the PRC, in February 2008.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. GUO Shaomu (郭少牧), aged 60, has been our independent non-executive director since November 23, 2020. He is primarily responsible for providing independent advice on the operations and management of our Company to our Board.

Mr. Guo has over 13 years of experience in investment banking in Hong Kong, during which time he accumulated ample knowledge in the financial industry. From February 2000 to February 2001, Mr. Guo served as an associate of corporate finance at Salomon Smith Barney, an investment bank principally engaged in providing financial services (an investment banking arm of Citigroup Inc.), where he was primarily responsible for supporting the marketing and execution efforts of the China team. From March 2001 to September 2005, Mr. Guo served as an associate and an associate director of global investment banking at HSBC Markets (Asia) Limited, an investment bank principally engaged in providing financial services, where he was primarily responsible for the execution of China-related transactions. From October 2005 to April 2007, Mr. Guo served as a vice president and a director of the real estate team at J.P. Morgan Investment Banking Asia, an investment bank principally engaged in financial services, where he was primarily responsible for marketing efforts covering the real estate sector in the PRC. From April 2007 to April 2013, Mr. Guo served as a director and a managing director of the real estate team at Morgan Stanley Investment Banking Asia, an investment bank primarily engaged in providing financial services, where he was one of the key members responsible for the business in the real estate sector in the Greater China region.

Mr. Guo has served as an independent non-executive director of Yida China Holdings Limited, a property developer listed on the Main Board of the Stock Exchange (stock code: 3639.HK), since June 2014, Fantasia Holdings Group Co., Limited, a property developer listed on the Main Board of the Stock Exchange (stock code: 1777.HK), since February 2015. Moreover, Mr. Guo served as an independent non-executive director of GalaxyCore Inc. (格科微有限公司), a

company listed on the Sci-Tech Board of the Shanghai Stock Exchange (stock code: 688728.SH) between March 2020 and March 2026, Ganglong China Property Group Limited (港龍中國地產集團有限公司), a property developer listed on the Main Board of the Stock Exchange (stock code: 6968.HK) between June 2020 and December 2023, and Sunkwan Properties Group Limited (上坤地產集團有限公司), a property developer listed on the Main Board of the Stock Exchange (stock code: 6900.HK) between October 2020 and July 2024, respectively.

Mr. Guo obtained his bachelor's degree in electrical engineering from Zhejiang University (浙江大學) in the PRC in July 1989, a master's degree in computer engineering from University of Southern California in May 1993. He received his master's degree in business administration from the School of Management of Yale University in May 1998.

Mr. FENG Xiangqian (馮向前), aged 40, has been our independent non-executive director since November 23, 2020. He is primarily responsible for providing independent advice on the operations and management of our Company to our Board.

Mr. Feng has over 18 years' experience in financial industry. Mr. Feng was a senior manager of Caitong Securities Corporation Limited (財通證券股份有限公司) from July 2007 to October 2010 where he was primarily responsible for initial public offering affairs. He was a business director of the investment banking department of Donghai Securities Corporation Limited (東海證券股份有限公司) from November 2010 to February 2014. He worked at Shenzhen Stock Exchange from March 2014 to March 2017. From August 2017 to July 2018, Mr. Feng was the investment director of the investment banking division of China Merchants Pingan AMC (深圳市招商平安資產管理有限責任公司). From April 2019 to June 2025, he worked at Xiangcai Securities Corporation Limited (湘財證券股份有限公司). Since July 2025, he has worked at Shenzhen Zhilian Kexun Technology Co., Ltd. (深圳市智聯科迅科技有限公司).

Mr. Feng obtained his bachelor's degree in biological science from Fudan University in July 2007 and his master's degree in finance from the University of Chinese Academy of Social Sciences (中國社會科學院大學) (formerly known as the Graduate School of Chinese Academy of Social Sciences (中國社會科學院研究生院)) in the PRC in June 2013. In October 2020, Mr. Feng received his certificate of senior economist from Shenzhen Municipal Human Resources and Social Security Bureau (深圳市人力資源和社會保障局). In addition, he has been a member of the Global Association of Risk Professionals as a financial risk manager since August 2019.

Mr. GONG Ping (龔平), aged 39, has been our independent non-executive director since January 11, 2021. He is primarily responsible for providing independent advice on the operations and management of our Company to our Board.

Mr. Gong has over 16 years' experience in auditing and financial management. Mr. Gong was the audit manager of the Shanghai branch of Ernst & Young Hua Ming (LLP) (安永華明會計師事務所(上海分所)特殊普通合夥) from December 2009 to March 2015. He then served as the deputy general manager of capital market division of Broad Greenstate Ecological Construction Group Company Limited (博大綠澤生態建設集團有限公司) from March 2015 to April 2018. Mr. Gong

served as the board secretary and chief financial officer of Dook Media Group Limited (讀客文化股份有限公司) from April 2018 to April 2024, the chief financial officer of Shanghai Liangyu Biotechnology Co., Ltd. (上海量預生物科技有限公司) from May 2024 to November 2024, and Zhonglu Co., Ltd. (中路股份有限公司) from November 2024 to December 2025. Mr. Gong has served as the chief financial officer of Shanghai Jirui Medical Technology Co., Ltd. (上海吉銳醫學科技有限公司) since December 2025.

Mr. Gong obtained his bachelor's degree in international accounting (U.S. division) from Shanghai University of Finance and Economics (上海財經大學) in July 2009. He has also obtained his master's degree in business administration (MBA) from the Shanghai Jiao Tong University in March 2021. Mr. Gong was named as a Shanghai Outstanding Accounting Talent in November 2024 by the Shanghai Municipal Finance Bureau and Shanghai National Accounting Institute. Mr. Gong has been a member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會, the "CICPA") since June 2015 and was duly admitted to full membership of Certified Public Accountants Association of Australia in February 2015.

NOMINATION POLICY

All board appointments will be based on meritocracy, and candidates will be considered against objective criteria, having due regard for the benefits of diversity on the Board.

In identifying and selecting suitable candidates for directorships, the Nomination Committee would consider the candidate's character, qualifications, experience, independence (for appointment of independent non-executive Directors), and Board diversity aspects, where appropriate, before making recommendation to the Board.

INTERESTS OF DIRECTORS IN THE COMPANY

As at the Latest Practicable Date, the interests and short positions of the Directors and chief executive in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) (i) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which were taken or deemed to have under such provisions of the SFO), or (ii) which were required, pursuant to section 352 of the SFO, to be

entered into the register maintained by the Company, or (iii) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code were as follows:

Name	Class of Shares	Capacity	Number of securities/nature of shares held	Approximate Percentage of Shareholding in Total Issued Share Capital of the Company	Approximate Percentage of Shareholding in Relevant Class of Shares
Wang Guohui[(1)]	Unlisted Shares	Beneficial Owner and Interest in controlled corporation	3,188,110/ Long Position	8.00%	38.56%
	H Shares		5,698,737/ Long Position	14.31%	18.05%
Zhang Kun[(2)]	Unlisted Shares	Beneficial owner and Interest of Spouse	1,566,488/ Long Position	3.93%	18.95%
	H Shares		1,209,688/ Long Position	3.04%	3.83%
Wei Jiawei[(3)]	H Shares	Beneficial Owner	240,000/ Long Position	0.60%	0.76%

Notes:

1. Mr. Wang Guohui directly holds 1,915,690 Unlisted Shares and 2,315,690 H Shares. Mr. Wang acts as the general partner of Ningbo Weizheng Self-Owned Capital Investment Partnership (LP) (寧波瑋鉦自有資金投資合夥企業(有限合夥)) ("**Weizheng Investment**") and Shanghai Zandaqian Enterprise Management Consulting Center (上海贊大乾企業管理諮詢中心) ("**Shanghai Zandaqian**") acts as the general partner of Ningbo Meishan Bonded Port Area Kaiyuan Investment Management Partnership (LP) (寧波梅山保稅港區楷遠投資管理合夥企業(有限合夥)) ("**Kaiyuan Investment**"), Ningbo Weiyu Self-Owned Capital Investment Partnership (LP) (寧波瑋鈺自有資金投資合夥企業(有限合夥)) ("**Weiyu Investment**") and Ningbo Weiyun Self-Owned Capital Investment Partnership (LP) (寧波瑋鋆自有資金投資合夥企業(有限合夥)) ("**Weiyun Investment**"). Shanghai Zandaqian is a sole proprietorship wholly owned by Mr. Wang. By virtue of the SFO, Mr. Wang Guohui is deemed to be interested in the Shares in which Weizheng Investment, Kaiyuan Investment, Weiyu Investment and Weiyun Investment are interested in and Shanghai Zandaqian is deemed to be interested in the Shares in which Kaiyuan Investment, Weiyu Investment and Weiyun Investment are interested in.

2. Ningbo Tongchuangsuwei Investment Partnership (LP) (寧波同創速維投資合夥企業(有限合夥)) ("**Tongchuangsuwei**") directly holds 869,330 Unlisted Shares and 512,530 H Shares. Ms. Zhang Kun directly holds 697,158 Unlisted Shares and 697,158 H Shares. Mr. Chai Yanpeng, as the general partner of

Tongchuangsuwei, is the spouse of Ms. Zhang Kun. By virtue of the SFO, Mr. Chai Yanpeng is deemed to be interested in the Shares in which Ms. Zhang Kun and Tongchuangsuwei is interested in and Ms. Zhang Kun is deemed to be interested in the Shares in which Mr. Chai Yanpeng is interested in.

3. Mr. Wei Jiawei is interested in 240,000 award shares granted to him pursuant to the Company's 2021 H Share Incentive Scheme which shall be vested in accordance with the terms of the grant between June 30, 2025 to June 30, 2027, and of which 72,000 award shares has already been vested.

PROPOSED REMUNERATIONS OF THE PROPOSED DIRECTORS OF THE THIRD SESSION OF THE BOARD

An ordinary resolution will be proposed at the EGM for the Shareholders to consider and approve the remuneration of the Directors for the Third Session of the Board as follows:

For Directors of the Third Session of the Board who hold executive positions in the Company, his/her remuneration shall be determined by the existing remuneration package of his/her positions at the Company. For Directors of the Third Session of the Board who do not hold executive positions in the Company, he/she shall be entitled to the following remuneration.

Mr. Chen Gang shall not be entitled to receive any remuneration for his position as a non-executive Director. Mr. Chen Shaoxiong and Mr. Lu Xubo will each be entitled to receive a remuneration of RMB120,000 (before tax) per year for their position as non-executive Directors.

Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping will be entitled to receive a remuneration of HKD260,000, HKD220,000 and RMB200,000 (before tax) per year for their positions as independent non-executive Directors, respectively, which was determined with reference to their existing remuneration and positions in the Company.

All aforesaid remunerations will be covered by the underlying service contracts.

FURTHER INFORMATION IN RELATION TO THE RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received written confirmation from each of Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping concerning their independence in accordance with the Hong Kong Listing Rules. The Nomination Committee and the Board also note that each of Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping does not have any relationship with any Director, senior management, substantial Shareholder or controlling Shareholder of the Company, nor is in any relationships or circumstances which would interfere with the exercise of his independent judgement as an independent non-executive Director. Accordingly, the Nomination Committee of the Company and the Board are satisfied that each of Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping remains independent. Having considered the biographical details of each of Mr.

Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping, the Nomination Committee is of the view that each of Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping, with different industry backgrounds including investment banking, financial industry and auditing and financial management respectively, brings his valuable perspectives, skills and experience to the Board to ensure the efficient and effective operation of the Board and alongside the other Directors, each of them contributes to ensuring that the interests of the Shareholders are taken into account and that relevant issues are subject to thorough and comprehensive consideration by the Board. The Nomination Committee is of the opinion that the re-election of each of them will contribute to the diversity of the Board. As such, the Board, having considered the recommendation of the Nomination Committee, recommends each of them to be re-elected as an independent non-executive director of the Third Session of the Board at the EGM.

Save as disclosed above and as at the Latest Practicable Date, each of the proposed Directors (i) has not held any directorship in any other listed company in the past three years of which the securities are listed on any securities market in Hong Kong or overseas; (ii) does not have other major appointments and professional qualifications; (iii) does not hold any other position with the Company or other members of the Group; (iv) does not have any other relationships with any of the other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there are no other matters concerning each of the proposed Directors that need to be brought to the attention of the Shareholders in connection with his/her re-election or election (as the case may be) and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

Save as disclosed above, none of the proposed Directors has or is proposed to have a service contract with any member of the Group (other than contracts expiring or determinable by the relevant employer within one year without the payment of compensation (other than statutory compensation)).

The Company will propose separate resolutions regarding the re-election and appointment of each of the proposed Directors of the Third Session of the Board and their remunerations at the EGM.

III. THE EGM

The EGM will be held at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC at 10:00 a.m. on November 13, 2026. Notice convening the EGM is set out in pages 20 to 22 of this circular and are available on the websites of the Hong Kong Stock Exchange (www.hkexnews.hk) and of the Company (www.heartcare.com.cn).

IV. CLOSURE OF REGISTER OF MEMBERS OF H SHARES AND ASCERTAINING OF ELIGIBILITY FOR ATTENDING THE EGM

The register of members of H Shares of the Company will be closed from Tuesday, November 10, 2026, to Friday, November 13, 2026, both days inclusive, during which no transfer of H Shares will be registered. In order to qualify for attending the EGM and vote for all resolutions to be submitted thereat, all transfer instruments of the H Shares together with the relevant share certificates shall be lodged with the Company's H Shares registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, before 4:30 p.m., on Monday, November 9, 2026 for registration. The record date for determining the entitlement of the Shareholders of the Company to attend and vote at the EGM will be Friday, November 13, 2026.

V. PROXY ARRANGEMENT

Enclosed herewith is the proxy form for the EGM. If you intend to appoint a proxy to attend the EGM, you are required to complete and return the proxy form in accordance with instructions printed thereon and return them to the Company's H Shares registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (in case of holders of H Shares) or the Company's headquarters at Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC (in case of holders of Domestic Shares and Unlisted Foreign Shares) as soon as possible and in any event no later than 24 hours before the time appointed for the EGM (i.e. no later than 10:00 a.m. on Thursday, November 12, 2026) or any adjournment thereof (for the proxy form (if any)). Completion and return of the proxy form will not preclude you from attending and voting at the EGM or any adjournment thereof in person if you so wish.

VI. VOTING BY POLL

In accordance with Rule 13.39(4) of the Hong Kong Listing Rules, any vote of Shareholders at the EGM must be taken by poll. As such, all the resolutions set out in the notice convening the EGM will be voted by poll. Save as disclosed in the circular, if any, no Shareholder will have a material interest in the matters to be approved and will be required to abstain from voting in respect of such resolutions.

VII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

VIII. RECOMMENDATION

The Directors (including the independent non-executive Directors) consider that all the above resolutions are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends all the Shareholders to vote in favour of the aforesaid resolutions to be proposed at the EGM.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai HeartCare Medical Technology Corporation Limited
上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2026 third extraordinary general meeting (the "**EGM**") of Shanghai HeartCare Medical Technology Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") will be held at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC on Friday, November 13, 2026 at 10:00 a.m. for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise defined, capitalized terms used in this notice shall have the same meanings as those defined in the circular of the Company dated October 29, 2026 (the "**Circular**").

ORDINARY RESOLUTIONS

1. To consider and approve the re-election and appointment of Mr. WANG Guohui as an executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

2. To consider and approve the re-election and appointment of Ms. ZHANG Kun as an executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and she shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

3. To consider and approve the re-election and appointment of Mr. WEI Jiawei as an executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

4. To consider and approve the re-election and appointment of Mr. CHEN Gang as a non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall not be entitled to receive any remuneration for his position as a non-executive Director.

5. To consider and approve the re-election and appointment of Mr. CHEN Shaoxiong as a non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of RMB120,000 per year (before tax).

6. To consider and approve the election and appointment of Mr. LU Xubo as a non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of RMB120,000 per year (before tax).

7. To consider and approve the re-election and appointment of Mr. GUO Shaomu as an independent non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of HKD260,000 per year (before tax).

8. To consider and approve the re-election and appointment of Mr. FENG Xiangqian as an independent non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of HKD220,000 per year (before tax).

9. To consider and approve the re-election and appointment of Mr. GONG Ping as an independent non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of RMB200,000 per year (before tax).

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, October 29, 2026

Notes:

1. Any voting at the EGM shall be taken by poll. Any Shareholder of the Company entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and, on a poll, vote instead of him/her. A proxy need not be a member of the Company.

2. The instrument appointing a proxy shall be in writing under the hand of the appointer or of his/her attorney duly authorized in writing or, if the appointer is a corporation, either under its seal or under the hand of any officer or attorney duly authorized.

3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of such power or authority, must be deposited with Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares) or the Company's registered office at Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC (for holders of Unlisted Shares) as soon as practicable but in any event not less than 24 hours before the time appointed for holding the EGM (i.e., at or before 10:00 a.m. on Thursday, November 12, 2026 (Hong Kong Time)), or any adjourned meeting thereof (as the case may be).

4. Completion and return of the form of proxy shall not preclude the Shareholders of the Company from attending and voting in person at the EGM or at any adjourned meeting thereof (as the case may be) should they so wish, and in such event, the form of proxy shall be deemed to be revoked.

5. Where there are joint registered holders of any share, any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the shares shall alone be entitled to vote in respect thereof.

6. For the purpose of determining the Shareholders of the Company entitled to attend and vote at the EGM, the register of members of the Company will be closed from Tuesday, November 10, 2026 to Friday, November 13, 2026 (both days inclusive). The record date for determining the entitlement of the Shareholders of the Company to attend and vote at the EGM will be Friday, November 13, 2026. In order to qualify for the entitlement to attend and vote at the above EGM, H Shareholders must lodge all transfer forms accompanied by the relevant H Share certificates with the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong by no later than 4:30 p.m. on Monday, November 9, 2026.

7. The EGM is expected to take less than half a day. Shareholders who attend the EGM shall be responsible for their own travel and accommodation expenses. Shareholders may contact the Investor Relations Department of the Company at +86 21 5897 5056 or ir@heartcare.com.cn for any enquiries in respect of the EGM.

8. Shareholders of the Company whose names appear on the register of members of the Company on Friday, November 13, 2026 will be entitled to attend and vote at the EGM or any adjourned meetings.

9. All times set out in this notice refer to Hong Kong local time.

As at the date of this notice, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.